Press release
Pulmonary Embolism Market Poised for Significant Growth, Projected to Reach US$3.5 Billion by 2031 - Key Trends and Market Insights
Pulmonary embolism (PE) is a life-threatening condition caused by the blockage of pulmonary arteries due to blood clots, often originating from deep vein thrombosis (DVT). The global pulmonary embolism market is witnessing substantial growth, driven by an increasing prevalence of risk factors such as obesity, cancer, smoking, and prolonged immobility. Advancements in diagnostic technologies and the growing adoption of minimally invasive treatments are further fueling market expansion.
Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.persistencemarketresearch.com/samples/34496
The market is projected to grow at a compound annual growth rate (CAGR) of 8.1% from 2024 to 2031, with an estimated revenue of US$1.5 billion in 2024, reaching US$3.5 billion by 2031. The medication segment is the dominant treatment type, owing to the widespread use of anticoagulants and thrombolytics. North America leads the market due to its well-established healthcare infrastructure, high disease prevalence, and significant investments in research and development.
Key Highlights from the Report
✦ Pulmonary embolism market to expand at an 8.1% CAGR (2024-2031).
✦ Rising prevalence of cancer and chronic diseases fueling market growth.
✦ North America dominates due to advanced healthcare facilities and high patient awareness.
✦ CT pulmonary angiography (CTPA) remains the gold standard for PE diagnosis.
✦ Increased focus on personalized medicine and minimally invasive procedures.
✦ Growing telemedicine adoption for remote patient monitoring and early detection.
Market Segmentation
The pulmonary embolism market is segmented based on product type, end-user, and distribution channels.
By Product Type:
Medications: Anticoagulants (blood thinners) and thrombolytics dominate the segment, ensuring effective clot dissolution and prevention.
Mechanical Devices: Used for thrombectomy and catheter-directed thrombolysis, primarily for severe cases.
Surgical Procedures: Reserved for high-risk cases requiring open embolectomy.
By End-User:
Hospitals: Major end-users due to the requirement for emergency care, advanced diagnostic tools, and post-procedural management.
Ambulatory Surgical Centers (ASCs): Gaining traction with the increasing demand for minimally invasive treatments.
Specialty Clinics: Focused on long-term PE management and follow-up care.
By Distribution Channel:
Hospital Pharmacies: Primary providers of anticoagulants and specialized PE treatment drugs.
Retail Pharmacies: Growing importance in outpatient PE management and long-term medication distribution.
Regional Insights
North America:
The leading market for pulmonary embolism treatments due to an aging population, rising obesity rates, and high healthcare expenditure. The presence of major pharmaceutical and medical device manufacturers further strengthens market dominance.
Europe:
The second-largest market, driven by government-funded healthcare systems and increasing awareness about early diagnosis and treatment.
Asia-Pacific:
Expected to witness the fastest growth due to increasing healthcare investments, rising disposable income, and improving access to advanced treatments.
Latin America & Middle East and Africa (MEA):
These regions show steady growth, driven by healthcare infrastructure improvements and increasing awareness about pulmonary embolism.
Market Drivers
The increasing prevalence of cancer, cardiovascular diseases, and obesity is significantly driving pulmonary embolism cases. Cancer patients undergoing chemotherapy are at a higher risk of developing PE, thereby increasing demand for effective treatments. Additionally, technological advancements in diagnostic imaging such as CT pulmonary angiography (CTPA) and point-of-care D-dimer testing have improved early diagnosis and treatment outcomes.
Market Restraints
A significant challenge hindering market growth is the high cost of treatment and medications, limiting accessibility in low-income regions. Furthermore, lack of awareness and delayed diagnosis contribute to underreported cases, affecting market penetration in emerging economies.
Market Opportunities
The pulmonary embolism market presents substantial opportunities through increased R&D investments in next-generation anticoagulants with fewer side effects. The integration of artificial intelligence (AI) in diagnostic imaging is also opening new avenues for faster and more accurate PE detection. Additionally, rising adoption of telemedicine for remote patient monitoring is expected to enhance market growth.
Reasons to Buy the Report
✔ In-depth analysis of market trends, drivers, and challenges influencing growth.
✔ Detailed segmentation insights for strategic business decisions.
✔ Regional market performance and future growth projections.
✔ Competitive landscape analysis covering key players and emerging trends.
✔ Coverage of recent technological advancements and innovations in PE treatment.
Frequently Asked Questions (FAQs)
How big is the pulmonary embolism market?
Who are the key players in the global pulmonary embolism market?
What is the projected growth rate of the market?
What is the market forecast for 2031?
Which region is estimated to dominate the industry through the forecast period?
Company Insights
• Bayer AG
• Johnson & Johnson
• Boehringer Ingelheim
• Pfizer Inc.
• Bristol-Myers Squibb
• Amgen Inc.
• AbbVie Inc.
• Anthos Therapeutics
• Astellas Pharma Inc.
• argenx SE
• Daiichi Sankyo Co. Ltd.
• F. Hoffmann-La Roche Ltd.
• Eli Lilly and Co.
• Gilead Sciences Inc.
• Medtronic Plc
• Inari Medical Inc.
• Novartis AG
• Sanofi
• Viatris Inc.
• Takeda Pharmaceutical Co. Ltd.
Significant Industry Developments
May 2024 - A new radiology procedure for pulmonary embolism was introduced, enhancing imaging precision for better diagnosis.
March 2024 - Pfizer Inc. launched a new anticoagulant, reducing bleeding risks while improving efficacy in PE treatment.
Conclusion
The pulmonary embolism market is witnessing robust growth due to increasing disease prevalence, technological advancements, and rising healthcare investments. With North America leading in revenue share, Asia-Pacific is emerging as a high-growth market due to improving healthcare infrastructure. Future market expansion will be driven by continued innovations in diagnosis, treatment, and personalized medicine. The growing focus on telemedicine and AI-driven diagnostics will further revolutionize pulmonary embolism management, making early detection and treatment more accessible worldwide.
Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web:
https://www.persistencemarketresearch.com
About Persistence Market Research:
At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.
Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pulmonary Embolism Market Poised for Significant Growth, Projected to Reach US$3.5 Billion by 2031 - Key Trends and Market Insights here
News-ID: 3932690 • Views: …
More Releases from Persistence Market Research
North America Wiring Devices Market Projected to Reach USD 26.46 Billion by 2031
Overview of the North America Wiring Devices Market
The North America wiring devices market is poised for steady growth over the forecast period, with its size estimated at US$ 18.96 billion in 2024, projected to reach US$ 26.46 billion by 2031, reflecting a CAGR of 4.9%. The market is witnessing substantial expansion due to increasing urbanization, a rising number of residential and commercial construction projects, and the adoption of energy-efficient and…
Global Forged Automotive Components Market Poised for Steady Growth, Projected t …
The global forged automotive components market is on a robust growth trajectory, currently valued at approximately US$ 50.3 billion in 2025 and forecasted to expand to US$ 70.7 billion by the end of 2032. This growth represents a compound annual growth rate (CAGR) of 5.0% over the coming decade, driven by increasing automotive production, technological advancements, and evolving consumer preferences toward durable, high-performance vehicle parts.
Forged automotive components are critical to…
Global Electric Cargo Bike Market Set to Accelerate at 11.9% CAGR, Reaching US$ …
The global electric cargo bike market is set to experience substantial growth over the coming decade, with Persistence Market Research (PMR) forecasting a compound annual growth rate (CAGR) of 11.9% from 2023 through 2032. Valued at approximately US$ 800 million in 2021, the market is expected to surge to a projected valuation of US$ 2.14 billion by the end of 2032. Notably, electric cargo bikes accounted for 66.2% of the…
Bicycle Bearings Market Set for Steady Growth with 6.5% CAGR Through 2032, Drive …
The global bicycle bearings market is poised for significant expansion over the forecast period of 2025 to 2032, according to the latest report released by Persistence Market Research. Valued at approximately US$ 5.99 billion in 2024, the market is projected to reach US$ 6.35 billion by 2025 and further escalate to nearly US$ 9.86 billion by 2032. This growth trajectory reflects a compound annual growth rate (CAGR) of 6.5%, underscoring…
More Releases for Pulmonary
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Global Pulmonary Embolism Market Size & Trends
According to a new market research report published by Global Market Estimates, the Global Pulmonary Embolism Market is exhibited at USD 1.59 billion in 2023 and is projected to surpass USD 3.15 billion in 2028, anticipated to grow at a CAGR of 8.4% from 2023 to 2028.
The rapid increase in the prevalence of cancer, increasing investment for healthcare infrastructure and rising research and development activities, high disposable income, rising demand…
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC…
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend of…
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs
Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated…
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic …
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market.
This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments…
